Antibody-Drug work by blocking the cd47 protein found on tumor cells. Cd47 acts as a "don't eat me" signal that prevents macrophages and other immune cells from destroying cancer cells.
By binding to the Anti-CD47 Drugs protein, these drugs disable this protective signaling and allow macrophages to recognize cancer cells as foreign and target them for phagocytosis and destruction. This novel approach essentially turns the body's natural defenses that cancer exploits against itself to attack tumors.
Key Advantages Of Targeting The Anti-CD47 Drugs -Sirpα Axis
Targeting the CD47-SIRPα pathway is an attractive strategy for cancer immunotherapy due to several unique advantages:
- Ubiquitous target: CD47 is universally highly expressed on tumor cells of various cancer types but only marginally expressed on normal cells. This means anti-CD47 treatments can potentially work against a wide variety of solid and hematological cancers.
- Activation of innate immunity: antibody-drug activate phagocytosis by macrophages, which are part of the body's innate immune system. Innate immunity provides a rapid and robust response compared to adaptive immunity mediated by T cells and antibodies.
- Synergy with other therapies: Studies show that blocking CD47 can enhance the antitumor effects of chemotherapy, radiotherapy, and other immunotherapy drugs like immune checkpoint inhibitors. This synergistic effect may improve clinical outcomes.
- Less likely drug resistance: CD47 is not a single target protein but modulates the interaction between cancer cells and macrophages. Multiple mechanisms would need to change together for tumors to develop resistance to such mechanism-based immunotherapy.
Clinical Development Progress
Given the promising preclinical results, several pharmaceutical companies are actively developing different types of antibody-drug. The lead clinical programs are:
- Magrolimab (5F9) by Forty Seven Inc: A monoclonal antibody in phase 1/2 trials showing responses in myelodysplastic syndrome and acute myeloid leukemia as monotherapy and in combination with azacitidine or venetoclax.
- TTI-621 by Trillium Therapeutics: A SIRPαFc fusion protein in phase 1 trials for solid tumors and hematological cancers. Study expansions ongoing.
- ALX148 by ALX Oncology: A fusion protein combining a CD47-binding domain with an albumin-binding domain showing activity in phase 1b solid tumor study.
- KTT-020 from Kite Pharma: A humanized anti-CD47 antibody entering phase 1 clinical trials for relapsed/refractory blood cancers.
- HGB-002 from Huan-Guo Biopharma: A humanized anti-CD47 monoclonal antibody cleared for phase 1 trials in China for advanced solid tumors.
Challenges And Future Outlook
While anti-CD47 immunotherapy holds immense promise, a few challenges remain in fully realizing its potential. Dosing needs to be optimized to avoid binding to red blood cells and triggering anemia side effects. Combination strategies will need to be further explored and developed. Biomarkers are required to identify patients most likely to respond.
Targeting the CD47-sirpα pathway has emerged as one of the most promising areas in cancer immunotherapy research. As clinical experience grows with the new drugs, anti-CD47 therapy may become an integral part of mainstream cancer treatment in the future, complementing and enhancing other immunotherapies and conventional therapies. With more advanced development, these agents could deliver on the goal of improving survival outcomes for patients with various refractory cancers.
Get more insights on this topic: https://www.trendingwebwire.com/anti-cd47-drugs-emerging-cancer-treatment-a-new-class-of-immunotherapies-shows-promise/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Comments
0 comment